aTyr Pharma, Inc. Common Stock (ATYR) Stock Price

ATYRStock

$0.54−89.91%52W

Market Cap$52.97M

P/E—

PEG Ratio—

Div yield—

Beta0.89

ATYR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-57.33%

Price vs S&P 500 (4W)8.21%

VGM Score26.72

Book Value / Share (Quarterly)$0.50

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-73.65%

Cash Flow / Share (Quarterly)$-0.56

Price vs S&P 500 (YTD)-43.86%

Net Profit Margin (TTM)-13549.47%

EPS (TTM)$-0.80

10-Day Avg Trading Volume0.54M

EPS Excl Extra (TTM)$-0.80

Revenue Growth (5Y)-55.14%

EPS (Annual)$-0.80

ROI (Annual)-108.41%

Net Profit Margin (5Y Avg)-16223.90%

Cash / Share (Quarterly)$0.59

ROA (Last FY)-79.69%

Revenue Growth TTM (YoY)-19.15%

EBITD / Share (TTM)$-0.83

ROE (5Y Avg)-70.24%

Operating Margin (TTM)-14076.32%

Cash Flow / Share (Annual)$-0.63

P/B Ratio1.17x

P/B Ratio (Quarterly)1.20x

Net Income / Employee (Annual)$-1,323,500

Net Interest Coverage (TTM)-123.28x

ROA (TTM)-74.41%

EPS Incl Extra (Annual)$-0.80

Current Ratio (Annual)5.30x

Quick Ratio (Quarterly)5.08x

3-Month Avg Trading Volume2.11M

52-Week Price Return-89.91%

Revenue / Employee (TTM)$3,400

P/S Ratio (Annual)299.48x

Asset Turnover (Annual)0.00x

52-Week High$6.50

Operating Margin (5Y Avg)-17182.53%

EPS Excl Extra (Annual)$-0.80

CapEx CAGR (5Y)-17.54%

26-Week Price Return-45.40%

Quick Ratio (Annual)5.25x

13-Week Price Return10.79%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)5.12x

Enterprise Value$41.29M

Revenue / Share Growth (5Y)-71.90%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$3,400

Pretax Margin (Annual)-39012.11%

Cash / Share (Annual)$0.80

3-Month Return Std Dev80.63%

Net Income / Employee (TTM)$-1,323,500

ROE (Last FY)-109.84%

Net Interest Coverage (Annual)-212.81x

EPS Basic Excl Extra (Annual)$-0.80

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$-0.80

ROI (TTM)-98.17%

P/S Ratio (TTM)299.48x

Pretax Margin (5Y Avg)-16224.82%

Revenue / Share (Annual)$0.00

Price vs S&P 500 (52W)-108.47%

Year-to-Date Return-31.03%

5-Day Price Return1.89%

EPS Normalized (Annual)$-0.80

ROA (5Y Avg)-52.83%

Net Profit Margin (Annual)-39009.47%

Month-to-Date Return11.18%

EBITD / Share (Annual)$-0.83

Operating Margin (Annual)-40856.32%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-69.13%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.80

P/B Ratio (Annual)1.14x

Pretax Margin (TTM)-13550.53%

Book Value / Share (Annual)$0.69

Price vs S&P 500 (13W)8.84%

Beta0.89x

Revenue / Share (TTM)$0.00

ROE (TTM)-99.62%

52-Week Low$0.40

gGradeF

mGradeD

vgmGradeD

ATYR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 7, 2026	-$0.13	-$0.11	+12.00%(+$0.02)
Q1 2026	May 15, 2026	-$0.14	-$0.11	+20.00%(+$0.03)
Q4 2025	Mar 5, 2026	-$0.17	-$0.14	+20.00%(+$0.03)
Q3 2025	Nov 6, 2025	-$0.18	-$0.26	-40.88%(-$0.08)
Q2 2025	Aug 7, 2025	-$0.18	-$0.22	-20.40%(-$0.04)

ATYR Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.69

3.80

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
ATYRaTyr Pharma, Inc. Common Stock	—	F	D	$0.54
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About aTyr Pharma, Inc. Common Stock

aTyr Pharma develops biotherapeutics using a proprietary tRNA synthetase platform. Its lead candidate, efzofitimod, is a clinical-stage treatment that targets NRP2 to address chronic inflammation and fibrosis, particularly in lung disease. The approach exploits a novel mechanism based on the extracellular signaling pathways of tRNA synthetases.